Abstracts tagged "Biomarkers"

Abstract Number: 1846 • 2015 ACR/ARHP Annual Meeting
IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis
Huihua Ding¹, Chandra Mohan¹ and Tianfu Wu², ¹Biomedical Engineering, University of Houston, Houston, TX, ²Department of Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the golden standard for the diagnosis…
Abstract Number: 2122 • 2015 ACR/ARHP Annual Meeting
A Novel Severity Score Based on Cardiac Neonatal Lupus Manifestations Serves As a Predictor and Outcome Measure of Morbidity in Anti-Ro Exposed Fetuses
Amit Saxena¹, Peter M. Izmirly¹, Sung Won Han², Paraskevi Briassouli¹, Tania Rivera³, Mark Halushka⁴, Hua Zhong⁵, Deborah Friedman⁶, Robert Clancy¹ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, New York University School of Medicine, New York, NY, ³Rheumatology, Scripps Memorial Hospital La Jolla, La Jolla, CA, ⁴Division of Cardiovascular Pathology, John Hopkins Pathology, Baltmore, MD, ⁵Population Health, New York University School of Medicine, New York, NY, ⁶Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro face a spectrum of fetal consequences when pregnant, from complete wellbeing to death from cardiac neonatal lupus (cardiac NL). Transplacental passage…
Abstract Number: 2701 • 2015 ACR/ARHP Annual Meeting
An Expansion of Rare Lineage Intestinal Microbes Characterize Rheumatoid Arthritis
Jun Chen¹, John M. Davis III², Eric L. Matteson³ and Veena Taneja⁴, ¹Health Sciences Research, Mayo Clinic, Rochesert, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: The adaptive immune response in Rheumatoid arthritis (RA) is influenced by an interaction between host genetics and environment, particularly the host microbiome. To define…
Abstract Number: 3126 • 2015 ACR/ARHP Annual Meeting
Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus
Mariana Postal, Aline Tamires Lapa, Karina O. Peliçari, Nailu A. Sinicato, Fernando A. Peres, Angela C. Gomes, Lilian TL Costallat, Fernando Cendes and Simone Appenzeller, Medicine, State University of Campinas, Campinas, Brazil
Background/Purpose: Cytokines and neuronal injury markers act as crucial mediators in the bidirectional signaling between the immune system and the brain and may be biomarkers…
Abstract Number: 532 • 2015 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression: Preliminary Results
Ozge Kockara¹, Sebnem Ataman², Merve Sibel Gungoren³, Filiz Akbiyik³ and Erdem Karabulut⁴, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ³Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disease that leads to bone erosion. Bone morphogenetic proteins (BMPs) have favourable effects in the recovery of bone…
Abstract Number: 803 • 2015 ACR/ARHP Annual Meeting
Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?
Lina Wirestam¹, Helena Enocsson², Christopher Sjöwall², Thomas Skogh², Maija-Leena Eloranta³, Lars Rönnblom³ and Jonas Wetterö², ¹Department of Clinical & Experimental Medicine, Rheumatology/AIR, Linkoping, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ³Medical Sciences, Rheumatology clinic, Uppsala, Sweden
Background/Purpose: The type I interferon (IFN) system is important in the pathogenesis of systemic lupus erythematosus (SLE). We have previously shown an inhibitory effect of…
Abstract Number: 1312 • 2015 ACR/ARHP Annual Meeting
Radiocarpal Cartilage Matrix Changes 3-Months after Anti-TNF Treatment for Rheumatoid Arthritis – Feasibility Study Using MR T1ρ� Imaging
Eric Ku¹, Valentina Pedoia², Matthew Tanaka³, Ursula Heilmeier¹, John Imboden⁴, Jonathan D. Graf⁵, Thomas M. Link⁶ and Xiaojuan Li⁷, ¹Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, ³University of California Berkeley, Berkeley, CA, ⁴Rheumatology, Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁶Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ⁷Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA
Background/Purpose: Standard assessment of Rheumatoid Arthritis (RA) on MRI relies on semi-quantitative joint space narrowing scores that are not sensitive to cartilage focal lesions or…
Abstract Number: 1847 • 2015 ACR/ARHP Annual Meeting
Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis
Ioannis Parodis¹, Huihua Ding², Agneta Zickert¹, Chandra Mohan² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). Renal biopsy is gold standard for evaluation of renal activity and damage…
Abstract Number: 2400 • 2015 ACR/ARHP Annual Meeting
Association Between Serum Urate and Osteoarthritis Progression in a Non-Obese Cohort
Svetlana Krasnokutsky¹, Mukundan Attur², Jonathan Samuels³, Fangfei Zhang⁴, Meng Chen⁴, Leon Ryback⁵, Steven B. Abramson⁶ and Michael H. Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY, ³Rheumatology, NYU - Hospital for Joint Diseases, New York, NY, ⁴Medicine-Rheumatology, NYU School of Medicine-NYU Hospital for Joint Diseases, New York, NY, ⁵Radiology-Musculoskeletal Radiology, New York University School of Medicine-NYU Hospital for Joint Diseases, New York, NY, ⁶Dept of Rheumatology/Medicine, Hosp for Joint Diseases/NYU, New York, NY
Background/Purpose: We recently reported an association between gout and osteoarthritis (OA) presence and severity, and a possible association between hyperuricemia and OA severity (Howard et…
Abstract Number: 2776 • 2015 ACR/ARHP Annual Meeting
Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Jason Ptacek, Ellen L. Berg and Alison O'Mahony, BioSeek, a division of DiscoveRx Corp., South San Francisco, CA
Background/Purpose: In vitro co-cultures of human primary cells, including immune cells, fibroblasts, smooth muscle, keratinocytes, epithelial or endothelial cells were developed to capture the complexity…
Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Xiang Guo¹, L Wang², G Illei³, P Brohawn¹, Brandon Higgs¹ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²MedImmune, Gaithersburg, MD, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
Abstract Number: 535 • 2015 ACR/ARHP Annual Meeting
Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis
Soshi Takahashi¹, Jun Saegusa², Ikuko Naka¹, Kosaku Tsuda¹, Takaichi Okano¹, Kengo Akashi¹, Miwa Nishida¹, Keisuke Nishimura², Sho Sendo², Yo Ueda¹, Akira Onishi³, Yoshinori Kogata², Goichi Kageyama² and Akio Morinobu², ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: To identify a serum biomarker for prediction of the response to biologics (Bio) in patients with rheumatoid arthritis (RA), we performed serum metabolomics analysis…
Abstract Number: 820 • 2015 ACR/ARHP Annual Meeting
Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Mikhail Olferiev, David Fernandez, Leila Khalili, Dina Greenman, Mary K. Crow and Kyriakos A. Kirou, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Decreases in peripheral blood levels of complement components of C3 and C4 are associated with SLE and often indicate a lupus flare. The aim…
Abstract Number: 1360 • 2015 ACR/ARHP Annual Meeting
Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease
Christine McDonald¹, Min Shen¹, Amrita Kabi¹, Craig Homer¹ and Qingping Yao², ¹Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Yao Syndrome (YS) is a systemic autoinflammatory disease formerly termed Nucleotide-binding oligomerization domain 2 (NOD2)-associated AutoInflammatory Disease (NAID) due to its association with specific…
Abstract Number: 1849 • 2015 ACR/ARHP Annual Meeting
Serum Axl and Tumor Necrosis Factor Receptor II Portend Long-Term Renal Outcome in Lupus Nephritis
Ioannis Parodis¹, Huihua Ding², Agneta Zickert¹, Chandra Mohan² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). Renal biopsy is gold standard for evaluation of renal activity and damage.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].